nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—PTGS1—Sulfasalazine—ankylosing spondylitis	0.103	0.187	CbGbCtD
Carvedilol—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0529	0.0962	CbGbCtD
Carvedilol—CYP1A1—Dexamethasone—ankylosing spondylitis	0.0512	0.0931	CbGbCtD
Carvedilol—CYP2E1—Dexamethasone—ankylosing spondylitis	0.0396	0.0719	CbGbCtD
Carvedilol—VCAM1—Beta5 beta6 beta7 and beta8 integrin cell surface interactions—EDIL3—ankylosing spondylitis	0.0385	0.184	CbGpPWpGaD
Carvedilol—ABCB1—Betamethasone—ankylosing spondylitis	0.0344	0.0625	CbGbCtD
Carvedilol—ABCB1—Prednisolone—ankylosing spondylitis	0.0339	0.0617	CbGbCtD
Carvedilol—ABCB1—Prednisone—ankylosing spondylitis	0.032	0.0583	CbGbCtD
Carvedilol—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0317	0.0576	CbGbCtD
Carvedilol—CYP3A4—Triamcinolone—ankylosing spondylitis	0.024	0.0437	CbGbCtD
Carvedilol—VCAM1—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.0212	0.101	CbGpPWpGaD
Carvedilol—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0206	0.0375	CbGbCtD
Carvedilol—CYP3A4—Betamethasone—ankylosing spondylitis	0.0206	0.0375	CbGbCtD
Carvedilol—CYP3A4—Prednisolone—ankylosing spondylitis	0.0203	0.037	CbGbCtD
Carvedilol—ABCB1—Dexamethasone—ankylosing spondylitis	0.02	0.0364	CbGbCtD
Carvedilol—CYP3A4—Prednisone—ankylosing spondylitis	0.0192	0.0349	CbGbCtD
Carvedilol—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0189	0.0343	CbGbCtD
Carvedilol—ABCB1—Methotrexate—ankylosing spondylitis	0.0161	0.0292	CbGbCtD
Carvedilol—CYP3A4—Dexamethasone—ankylosing spondylitis	0.012	0.0218	CbGbCtD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—KIR3DL1—ankylosing spondylitis	0.0111	0.0527	CbGpPWpGaD
Carvedilol—VEGFA—Beta3 integrin cell surface interactions—EDIL3—ankylosing spondylitis	0.00701	0.0334	CbGpPWpGaD
Carvedilol—VEGFA—Integrins in angiogenesis—EDIL3—ankylosing spondylitis	0.00516	0.0246	CbGpPWpGaD
Carvedilol—VCAM1—Beta2 integrin cell surface interactions—CD40LG—ankylosing spondylitis	0.00459	0.0219	CbGpPWpGaD
Carvedilol—SELE—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.00456	0.0218	CbGpPWpGaD
Carvedilol—VCAM1—Interferon gamma signaling—HLA-C—ankylosing spondylitis	0.00369	0.0176	CbGpPWpGaD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—HLA-C—ankylosing spondylitis	0.00365	0.0174	CbGpPWpGaD
Carvedilol—VEGFA—Hypertrophy Model—IL1A—ankylosing spondylitis	0.00238	0.0113	CbGpPWpGaD
Carvedilol—NPPB—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.00232	0.011	CbGpPWpGaD
Carvedilol—HIF1A—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.00227	0.0108	CbGpPWpGaD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—CD40LG—ankylosing spondylitis	0.00227	0.0108	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.00222	0.0106	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00221	0.0105	CbGpPWpGaD
Carvedilol—VCAM1—Interferon gamma signaling—HLA-B—ankylosing spondylitis	0.00218	0.0104	CbGpPWpGaD
Carvedilol—VCAM1—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.00218	0.0104	CbGpPWpGaD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—HLA-B—ankylosing spondylitis	0.00216	0.0103	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.00214	0.0102	CbGpPWpGaD
Carvedilol—GJA1—AP-1 transcription factor network—IL10—ankylosing spondylitis	0.00209	0.00994	CbGpPWpGaD
Carvedilol—VCAM1—Interferon gamma signaling—HLA-A—ankylosing spondylitis	0.00202	0.00964	CbGpPWpGaD
Carvedilol—HIF1A—AP-1 transcription factor network—IL10—ankylosing spondylitis	0.00201	0.00958	CbGpPWpGaD
Carvedilol—VCAM1—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—HLA-A—ankylosing spondylitis	0.002	0.00953	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00197	0.00937	CbGpPWpGaD
Carvedilol—VEGFA—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00189	0.009	CbGpPWpGaD
Carvedilol—GJA1—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	0.00184	0.00876	CbGpPWpGaD
Carvedilol—VCAM1—Interferon Signaling—HLA-C—ankylosing spondylitis	0.0018	0.00859	CbGpPWpGaD
Carvedilol—HIF1A—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	0.00177	0.00845	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.00153	0.00731	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.00148	0.00705	CbGpPWpGaD
Carvedilol—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.0014	0.00669	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.00138	0.00658	CbGpPWpGaD
Carvedilol—GJA1—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.00135	0.00644	CbGpPWpGaD
Carvedilol—GJA1—Cortisone acetate—Methylprednisolone—ankylosing spondylitis	0.0013	0.102	CbGdCrCtD
Carvedilol—VEGFA—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00127	0.00604	CbGpPWpGaD
Carvedilol—VCAM1—synovial membrane of synovial joint—ankylosing spondylitis	0.00125	0.508	CbGeAlD
Carvedilol—KCNH2—Hematopoietic Stem Cell Differentiation—IL1A—ankylosing spondylitis	0.00124	0.0059	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.0012	0.00574	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—KIR3DL1—ankylosing spondylitis	0.00119	0.00568	CbGpPWpGaD
Carvedilol—GJA1—Cortisone acetate—Prednisone—ankylosing spondylitis	0.00119	0.0929	CbGdCrCtD
Carvedilol—GJA1—Cortisone acetate—Prednisolone—ankylosing spondylitis	0.00116	0.0907	CbGdCrCtD
Carvedilol—VEGFA—Allograft Rejection—IL17A—ankylosing spondylitis	0.00116	0.00552	CbGpPWpGaD
Carvedilol—PTGS1—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.00114	0.00542	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00113	0.00538	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.00111	0.00528	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.0011	0.00527	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.0011	0.00523	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—IL12B—ankylosing spondylitis	0.00108	0.00513	CbGpPWpGaD
Carvedilol—VCAM1—Interferon Signaling—HLA-B—ankylosing spondylitis	0.00107	0.00508	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.00107	0.00508	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.00106	0.00505	CbGpPWpGaD
Carvedilol—SELE—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	0.00105	0.00502	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.00105	0.00498	CbGpPWpGaD
Carvedilol—VCAM1—Interferon Signaling—HLA-A—ankylosing spondylitis	0.000988	0.00471	CbGpPWpGaD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.000979	0.00467	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000925	0.00441	CbGpPWpGaD
Carvedilol—GJA1—Rimexolone—Methylprednisolone—ankylosing spondylitis	0.000878	0.0685	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Dexamethasone—ankylosing spondylitis	0.000864	0.0674	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Betamethasone—ankylosing spondylitis	0.000864	0.0674	CbGdCrCtD
Carvedilol—GJA1—Rimexolone—Triamcinolone—ankylosing spondylitis	0.000844	0.0659	CbGdCrCtD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000839	0.004	CbGpPWpGaD
Carvedilol—VCAM1—Extracellular matrix organization—MMP3—ankylosing spondylitis	0.000834	0.00398	CbGpPWpGaD
Carvedilol—ADRB3—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000822	0.00392	CbGpPWpGaD
Carvedilol—GJA1—Rimexolone—Prednisone—ankylosing spondylitis	0.000801	0.0625	CbGdCrCtD
Carvedilol—VEGFA—Allograft Rejection—IL1A—ankylosing spondylitis	0.000792	0.00378	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—IL10—ankylosing spondylitis	0.000788	0.00375	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000788	0.00375	CbGpPWpGaD
Carvedilol—GJA1—Rimexolone—Prednisolone—ankylosing spondylitis	0.000782	0.061	CbGdCrCtD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000753	0.00359	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000749	0.00357	CbGpPWpGaD
Carvedilol—HIF1A—Disease—ANTXR2—ankylosing spondylitis	0.000739	0.00352	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IL1R2—ankylosing spondylitis	0.000722	0.00344	CbGpPWpGaD
Carvedilol—XDH—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000713	0.0034	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000712	0.00339	CbGpPWpGaD
Carvedilol—HIF1A—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000699	0.00333	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000694	0.00331	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—ERAP1—ankylosing spondylitis	0.000685	0.00326	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.00066	0.00314	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000648	0.00309	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000643	0.00306	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000639	0.00304	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CARD9—ankylosing spondylitis	0.000626	0.00298	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000579	0.00276	CbGpPWpGaD
Carvedilol—GJA1—Progesterone—Prednisolone—ankylosing spondylitis	0.000569	0.0444	CbGdCrCtD
Carvedilol—GJA1—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000523	0.00249	CbGpPWpGaD
Carvedilol—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000515	0.00245	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000494	0.00236	CbGpPWpGaD
Carvedilol—ADRB1—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000488	0.00233	CbGpPWpGaD
Carvedilol—ADRB2—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000477	0.00228	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—B3GNT2—ankylosing spondylitis	0.000473	0.00226	CbGpPWpGaD
Carvedilol—HIF1A—Adipogenesis—TNF—ankylosing spondylitis	0.000466	0.00222	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000462	0.0022	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.00046	0.00219	CbGpPWpGaD
Carvedilol—ADRB3—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000457	0.00218	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000457	0.00218	CbGpPWpGaD
Carvedilol—HIF1A—Disease—B3GNT2—ankylosing spondylitis	0.000436	0.00208	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000418	0.00199	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000417	0.00199	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000414	0.00198	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00041	0.00195	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000403	0.00192	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000403	0.00192	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-C—ankylosing spondylitis	0.000393	0.00187	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000392	0.00187	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000392	0.00187	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000383	0.00183	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000358	0.00171	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000355	0.00169	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IL1RN—ankylosing spondylitis	0.000342	0.00163	CbGpPWpGaD
Carvedilol—Angiopathy—Prednisone—ankylosing spondylitis	0.000336	0.0015	CcSEcCtD
Carvedilol—Confusional state—Methylprednisolone—ankylosing spondylitis	0.000335	0.00149	CcSEcCtD
Carvedilol—Immune system disorder—Prednisone—ankylosing spondylitis	0.000335	0.00149	CcSEcCtD
Carvedilol—Malaise—Betamethasone—ankylosing spondylitis	0.000334	0.00149	CcSEcCtD
Carvedilol—Malaise—Dexamethasone—ankylosing spondylitis	0.000334	0.00149	CcSEcCtD
Carvedilol—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000334	0.00159	CbGpPWpGaD
Carvedilol—Oedema—Triamcinolone—ankylosing spondylitis	0.000333	0.00148	CcSEcCtD
Carvedilol—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000333	0.00148	CcSEcCtD
Carvedilol—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.000333	0.00159	CbGpPWpGaD
Carvedilol—Vertigo—Betamethasone—ankylosing spondylitis	0.000333	0.00148	CcSEcCtD
Carvedilol—Vertigo—Dexamethasone—ankylosing spondylitis	0.000333	0.00148	CcSEcCtD
Carvedilol—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000333	0.00148	CcSEcCtD
Carvedilol—Syncope—Betamethasone—ankylosing spondylitis	0.000332	0.00148	CcSEcCtD
Carvedilol—Syncope—Dexamethasone—ankylosing spondylitis	0.000332	0.00148	CcSEcCtD
Carvedilol—Infection—Triamcinolone—ankylosing spondylitis	0.000331	0.00147	CcSEcCtD
Carvedilol—Infection—Methylprednisolone—ankylosing spondylitis	0.00033	0.00147	CcSEcCtD
Carvedilol—Haematuria—Methotrexate—ankylosing spondylitis	0.000329	0.00146	CcSEcCtD
Carvedilol—Shock—Triamcinolone—ankylosing spondylitis	0.000328	0.00146	CcSEcCtD
Carvedilol—Insomnia—Prednisolone—ankylosing spondylitis	0.000328	0.00146	CcSEcCtD
Carvedilol—Alopecia—Prednisone—ankylosing spondylitis	0.000328	0.00146	CcSEcCtD
Carvedilol—Shock—Methylprednisolone—ankylosing spondylitis	0.000327	0.00145	CcSEcCtD
Carvedilol—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000326	0.00145	CcSEcCtD
Carvedilol—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000326	0.00145	CcSEcCtD
Carvedilol—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000325	0.00145	CcSEcCtD
Carvedilol—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000325	0.00145	CcSEcCtD
Carvedilol—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000325	0.00144	CcSEcCtD
Carvedilol—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000323	0.00144	CcSEcCtD
Carvedilol—XDH—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000323	0.00154	CbGpPWpGaD
Carvedilol—Malnutrition—Prednisone—ankylosing spondylitis	0.000323	0.00143	CcSEcCtD
Carvedilol—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000322	0.00143	CcSEcCtD
Carvedilol—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000321	0.00143	CcSEcCtD
Carvedilol—Convulsion—Dexamethasone—ankylosing spondylitis	0.000321	0.00143	CcSEcCtD
Carvedilol—Convulsion—Betamethasone—ankylosing spondylitis	0.000321	0.00143	CcSEcCtD
Carvedilol—Hypertension—Dexamethasone—ankylosing spondylitis	0.00032	0.00142	CcSEcCtD
Carvedilol—Hypertension—Betamethasone—ankylosing spondylitis	0.00032	0.00142	CcSEcCtD
Carvedilol—Myalgia—Betamethasone—ankylosing spondylitis	0.000315	0.0014	CcSEcCtD
Carvedilol—Myalgia—Dexamethasone—ankylosing spondylitis	0.000315	0.0014	CcSEcCtD
Carvedilol—Discomfort—Dexamethasone—ankylosing spondylitis	0.000312	0.00139	CcSEcCtD
Carvedilol—Discomfort—Betamethasone—ankylosing spondylitis	0.000312	0.00139	CcSEcCtD
Carvedilol—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000311	0.00138	CcSEcCtD
Carvedilol—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000311	0.00138	CcSEcCtD
Carvedilol—Pain—Prednisolone—ankylosing spondylitis	0.00031	0.00138	CcSEcCtD
Carvedilol—Haemorrhage—Methotrexate—ankylosing spondylitis	0.00031	0.00138	CcSEcCtD
Carvedilol—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000307	0.00137	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000306	0.00136	CcSEcCtD
Carvedilol—Vision blurred—Prednisone—ankylosing spondylitis	0.000304	0.00135	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000304	0.00135	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000304	0.00135	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000303	0.00135	CcSEcCtD
Carvedilol—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000302	0.00134	CcSEcCtD
Carvedilol—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000302	0.00134	CcSEcCtD
Carvedilol—Oedema—Betamethasone—ankylosing spondylitis	0.000302	0.00134	CcSEcCtD
Carvedilol—Oedema—Dexamethasone—ankylosing spondylitis	0.000302	0.00134	CcSEcCtD
Carvedilol—VEGFA—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000302	0.00144	CbGpPWpGaD
Carvedilol—Insomnia—Triamcinolone—ankylosing spondylitis	0.000301	0.00134	CcSEcCtD
Carvedilol—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000301	0.00134	CcSEcCtD
Carvedilol—Infection—Betamethasone—ankylosing spondylitis	0.0003	0.00134	CcSEcCtD
Carvedilol—Infection—Dexamethasone—ankylosing spondylitis	0.0003	0.00134	CcSEcCtD
Carvedilol—VCAM1—Immune System—CD79A—ankylosing spondylitis	0.0003	0.00143	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—TNF—ankylosing spondylitis	0.0003	0.00143	CbGpPWpGaD
Carvedilol—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000299	0.00133	CcSEcCtD
Carvedilol—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000299	0.00133	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000299	0.00133	CcSEcCtD
Carvedilol—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000299	0.00133	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—ankylosing spondylitis	0.000299	0.00133	CcSEcCtD
Carvedilol—ADRB3—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000298	0.00142	CbGpPWpGaD
Carvedilol—Anaemia—Prednisone—ankylosing spondylitis	0.000298	0.00133	CcSEcCtD
Carvedilol—ADRA1D—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000298	0.00142	CbGpPWpGaD
Carvedilol—Shock—Betamethasone—ankylosing spondylitis	0.000298	0.00132	CcSEcCtD
Carvedilol—Shock—Dexamethasone—ankylosing spondylitis	0.000298	0.00132	CcSEcCtD
Carvedilol—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000297	0.00132	CcSEcCtD
Carvedilol—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000296	0.00132	CcSEcCtD
Carvedilol—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000296	0.00132	CcSEcCtD
Carvedilol—Tachycardia—Betamethasone—ankylosing spondylitis	0.000295	0.00131	CcSEcCtD
Carvedilol—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000295	0.00131	CcSEcCtD
Carvedilol—Angioedema—Prednisone—ankylosing spondylitis	0.000295	0.00131	CcSEcCtD
Carvedilol—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000293	0.0013	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000293	0.0013	CcSEcCtD
Carvedilol—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000293	0.0013	CcSEcCtD
Carvedilol—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000292	0.0013	CcSEcCtD
Carvedilol—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000292	0.0013	CcSEcCtD
Carvedilol—Malaise—Prednisone—ankylosing spondylitis	0.000291	0.00129	CcSEcCtD
Carvedilol—Vertigo—Prednisone—ankylosing spondylitis	0.00029	0.00129	CcSEcCtD
Carvedilol—Syncope—Prednisone—ankylosing spondylitis	0.000289	0.00129	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—ankylosing spondylitis	0.000289	0.00128	CcSEcCtD
Carvedilol—Anorexia—Betamethasone—ankylosing spondylitis	0.000288	0.00128	CcSEcCtD
Carvedilol—Anorexia—Dexamethasone—ankylosing spondylitis	0.000288	0.00128	CcSEcCtD
Carvedilol—Urticaria—Prednisolone—ankylosing spondylitis	0.000288	0.00128	CcSEcCtD
Carvedilol—Fatigue—Triamcinolone—ankylosing spondylitis	0.000287	0.00128	CcSEcCtD
Carvedilol—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000287	0.00127	CcSEcCtD
Carvedilol—Pain—Triamcinolone—ankylosing spondylitis	0.000285	0.00127	CcSEcCtD
Carvedilol—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000284	0.00126	CcSEcCtD
Carvedilol—Hypotension—Betamethasone—ankylosing spondylitis	0.000283	0.00126	CcSEcCtD
Carvedilol—Hypotension—Dexamethasone—ankylosing spondylitis	0.000283	0.00126	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—ankylosing spondylitis	0.000281	0.00125	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—ankylosing spondylitis	0.00028	0.00124	CcSEcCtD
Carvedilol—Convulsion—Prednisone—ankylosing spondylitis	0.00028	0.00124	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000279	0.00124	CcSEcCtD
Carvedilol—Hypertension—Prednisone—ankylosing spondylitis	0.000279	0.00124	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000276	0.00123	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000276	0.00123	CcSEcCtD
Carvedilol—Myalgia—Prednisone—ankylosing spondylitis	0.000275	0.00122	CcSEcCtD
Carvedilol—Arthralgia—Prednisone—ankylosing spondylitis	0.000275	0.00122	CcSEcCtD
Carvedilol—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000275	0.00122	CcSEcCtD
Carvedilol—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000274	0.00122	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—ankylosing spondylitis	0.000274	0.00122	CcSEcCtD
Carvedilol—Insomnia—Dexamethasone—ankylosing spondylitis	0.000274	0.00122	CcSEcCtD
Carvedilol—Insomnia—Betamethasone—ankylosing spondylitis	0.000274	0.00122	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000273	0.00121	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000272	0.00121	CcSEcCtD
Carvedilol—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000272	0.00121	CcSEcCtD
Carvedilol—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000272	0.00121	CcSEcCtD
Carvedilol—ADRB1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000272	0.00129	CbGpPWpGaD
Carvedilol—Discomfort—Prednisone—ankylosing spondylitis	0.000271	0.00121	CcSEcCtD
Carvedilol—Malnutrition—Methotrexate—ankylosing spondylitis	0.00027	0.0012	CcSEcCtD
Carvedilol—ADRA2B—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000269	0.00128	CbGpPWpGaD
Carvedilol—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000267	0.00119	CcSEcCtD
Carvedilol—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000266	0.00118	CcSEcCtD
Carvedilol—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000266	0.00118	CcSEcCtD
Carvedilol—ADRB2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000266	0.00127	CbGpPWpGaD
Carvedilol—Urticaria—Triamcinolone—ankylosing spondylitis	0.000265	0.00118	CcSEcCtD
Carvedilol—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000264	0.00117	CcSEcCtD
Carvedilol—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000263	0.00117	CcSEcCtD
Carvedilol—Oedema—Prednisone—ankylosing spondylitis	0.000263	0.00117	CcSEcCtD
Carvedilol—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000263	0.00117	CcSEcCtD
Carvedilol—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000263	0.00117	CcSEcCtD
Carvedilol—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000263	0.00117	CcSEcCtD
Carvedilol—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000263	0.00117	CcSEcCtD
Carvedilol—Infection—Prednisone—ankylosing spondylitis	0.000262	0.00116	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000261	0.00116	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000261	0.00116	CcSEcCtD
Carvedilol—Back pain—Methotrexate—ankylosing spondylitis	0.000261	0.00116	CcSEcCtD
Carvedilol—Fatigue—Betamethasone—ankylosing spondylitis	0.000261	0.00116	CcSEcCtD
Carvedilol—Fatigue—Dexamethasone—ankylosing spondylitis	0.000261	0.00116	CcSEcCtD
Carvedilol—Shock—Prednisone—ankylosing spondylitis	0.000259	0.00115	CcSEcCtD
Carvedilol—Pain—Dexamethasone—ankylosing spondylitis	0.000259	0.00115	CcSEcCtD
Carvedilol—Pain—Betamethasone—ankylosing spondylitis	0.000259	0.00115	CcSEcCtD
Carvedilol—Tachycardia—Prednisone—ankylosing spondylitis	0.000257	0.00114	CcSEcCtD
Carvedilol—Skin disorder—Prednisone—ankylosing spondylitis	0.000256	0.00114	CcSEcCtD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000255	0.00122	CbGpPWpGaD
Carvedilol—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000255	0.00113	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—ankylosing spondylitis	0.000254	0.00113	CcSEcCtD
Carvedilol—ADRA2C—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000251	0.0012	CbGpPWpGaD
Carvedilol—Anorexia—Prednisone—ankylosing spondylitis	0.000251	0.00112	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.00025	0.00111	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—ankylosing spondylitis	0.000249	0.00111	CcSEcCtD
Carvedilol—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000249	0.00111	CcSEcCtD
Carvedilol—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000249	0.00111	CcSEcCtD
Carvedilol—ADRA1B—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000247	0.00118	CbGpPWpGaD
Carvedilol—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000247	0.0011	CcSEcCtD
Carvedilol—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000247	0.0011	CcSEcCtD
Carvedilol—VCAM1—Immune System—IL1A—ankylosing spondylitis	0.000246	0.00117	CbGpPWpGaD
Carvedilol—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000246	0.00109	CcSEcCtD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000245	0.00117	CbGpPWpGaD
Carvedilol—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000245	0.00109	CcSEcCtD
Carvedilol—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000245	0.00117	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD40LG—ankylosing spondylitis	0.000244	0.00117	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000244	0.00116	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000244	0.00116	CbGpPWpGaD
Carvedilol—Malaise—Methotrexate—ankylosing spondylitis	0.000243	0.00108	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—ankylosing spondylitis	0.000242	0.00108	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—ankylosing spondylitis	0.000241	0.00107	CcSEcCtD
Carvedilol—Urticaria—Betamethasone—ankylosing spondylitis	0.00024	0.00107	CcSEcCtD
Carvedilol—Urticaria—Dexamethasone—ankylosing spondylitis	0.00024	0.00107	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00024	0.00107	CcSEcCtD
Carvedilol—Dizziness—Prednisolone—ankylosing spondylitis	0.00024	0.00107	CcSEcCtD
Carvedilol—Asthenia—Triamcinolone—ankylosing spondylitis	0.000239	0.00106	CcSEcCtD
Carvedilol—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000239	0.00106	CcSEcCtD
Carvedilol—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000239	0.00106	CcSEcCtD
Carvedilol—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000239	0.00106	CcSEcCtD
Carvedilol—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000239	0.00106	CcSEcCtD
Carvedilol—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000239	0.00106	CcSEcCtD
Carvedilol—Insomnia—Prednisone—ankylosing spondylitis	0.000238	0.00106	CcSEcCtD
Carvedilol—Paraesthesia—Prednisone—ankylosing spondylitis	0.000236	0.00105	CcSEcCtD
Carvedilol—Pruritus—Triamcinolone—ankylosing spondylitis	0.000236	0.00105	CcSEcCtD
Carvedilol—Cough—Methotrexate—ankylosing spondylitis	0.000235	0.00105	CcSEcCtD
Carvedilol—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000235	0.00105	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—ankylosing spondylitis	0.000234	0.00104	CcSEcCtD
Carvedilol—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000233	0.00111	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000233	0.00111	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-B—ankylosing spondylitis	0.000233	0.00111	CbGpPWpGaD
Carvedilol—Dyspepsia—Prednisone—ankylosing spondylitis	0.000232	0.00103	CcSEcCtD
Carvedilol—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000232	0.0011	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.00023	0.0011	CbGpPWpGaD
Carvedilol—Myalgia—Methotrexate—ankylosing spondylitis	0.00023	0.00102	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—ankylosing spondylitis	0.00023	0.00102	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—ankylosing spondylitis	0.00023	0.00102	CcSEcCtD
Carvedilol—Decreased appetite—Prednisone—ankylosing spondylitis	0.000229	0.00102	CcSEcCtD
Carvedilol—Rash—Prednisolone—ankylosing spondylitis	0.000229	0.00102	CcSEcCtD
Carvedilol—Dermatitis—Prednisolone—ankylosing spondylitis	0.000228	0.00102	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000228	0.00101	CcSEcCtD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000228	0.00108	CbGpPWpGaD
Carvedilol—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000228	0.00101	CcSEcCtD
Carvedilol—Fatigue—Prednisone—ankylosing spondylitis	0.000227	0.00101	CcSEcCtD
Carvedilol—Headache—Prednisolone—ankylosing spondylitis	0.000227	0.00101	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—ankylosing spondylitis	0.000227	0.00101	CcSEcCtD
Carvedilol—Constipation—Prednisone—ankylosing spondylitis	0.000225	0.001	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—ankylosing spondylitis	0.000222	0.000987	CcSEcCtD
Carvedilol—Dizziness—Triamcinolone—ankylosing spondylitis	0.00022	0.00098	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.00022	0.000979	CcSEcCtD
Carvedilol—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00022	0.000978	CcSEcCtD
Carvedilol—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00022	0.00105	CbGpPWpGaD
Carvedilol—Infection—Methotrexate—ankylosing spondylitis	0.000219	0.000972	CcSEcCtD
Carvedilol—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000217	0.000965	CcSEcCtD
Carvedilol—Asthenia—Dexamethasone—ankylosing spondylitis	0.000217	0.000965	CcSEcCtD
Carvedilol—Asthenia—Betamethasone—ankylosing spondylitis	0.000217	0.000965	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000216	0.000958	CcSEcCtD
Carvedilol—VCAM1—Immune System—HLA-A—ankylosing spondylitis	0.000215	0.00103	CbGpPWpGaD
Carvedilol—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000215	0.000958	CcSEcCtD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000215	0.00103	CbGpPWpGaD
Carvedilol—Nausea—Prednisolone—ankylosing spondylitis	0.000215	0.000957	CcSEcCtD
Carvedilol—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000215	0.00102	CbGpPWpGaD
Carvedilol—Pruritus—Betamethasone—ankylosing spondylitis	0.000214	0.000951	CcSEcCtD
Carvedilol—Pruritus—Dexamethasone—ankylosing spondylitis	0.000214	0.000951	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—ankylosing spondylitis	0.000214	0.000951	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000213	0.000946	CcSEcCtD
Carvedilol—Vomiting—Triamcinolone—ankylosing spondylitis	0.000212	0.000942	CcSEcCtD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000212	0.00101	CbGpPWpGaD
Carvedilol—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000211	0.00094	CcSEcCtD
Carvedilol—Rash—Triamcinolone—ankylosing spondylitis	0.00021	0.000934	CcSEcCtD
Carvedilol—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00021	0.000933	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—ankylosing spondylitis	0.00021	0.000933	CcSEcCtD
Carvedilol—Rash—Methylprednisolone—ankylosing spondylitis	0.00021	0.000932	CcSEcCtD
Carvedilol—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000209	0.000931	CcSEcCtD
Carvedilol—Urticaria—Prednisone—ankylosing spondylitis	0.000209	0.00093	CcSEcCtD
Carvedilol—HIF1A—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000209	0.000997	CbGpPWpGaD
Carvedilol—Headache—Triamcinolone—ankylosing spondylitis	0.000209	0.000928	CcSEcCtD
Carvedilol—Headache—Methylprednisolone—ankylosing spondylitis	0.000208	0.000926	CcSEcCtD
Carvedilol—Abdominal pain—Prednisone—ankylosing spondylitis	0.000208	0.000926	CcSEcCtD
Carvedilol—Body temperature increased—Prednisone—ankylosing spondylitis	0.000208	0.000926	CcSEcCtD
Carvedilol—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000207	0.00092	CcSEcCtD
Carvedilol—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000207	0.00092	CcSEcCtD
Carvedilol—SELE—tendon—ankylosing spondylitis	0.000206	0.0835	CbGeAlD
Carvedilol—Hypotension—Methotrexate—ankylosing spondylitis	0.000206	0.000914	CcSEcCtD
Carvedilol—VCAM1—Immune System—CRP—ankylosing spondylitis	0.000206	0.00098	CbGpPWpGaD
Carvedilol—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000204	0.000973	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000204	0.000971	CbGpPWpGaD
Carvedilol—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000201	0.000892	CcSEcCtD
Carvedilol—Dizziness—Dexamethasone—ankylosing spondylitis	0.0002	0.000889	CcSEcCtD
Carvedilol—Dizziness—Betamethasone—ankylosing spondylitis	0.0002	0.000889	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—ankylosing spondylitis	0.000199	0.000885	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000199	0.0155	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000199	0.0155	CbGdCrCtD
Carvedilol—Nausea—Triamcinolone—ankylosing spondylitis	0.000198	0.00088	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000198	0.000879	CcSEcCtD
Carvedilol—Nausea—Methylprednisolone—ankylosing spondylitis	0.000198	0.000878	CcSEcCtD
Carvedilol—VCAM1—Immune System—TLR4—ankylosing spondylitis	0.000197	0.000939	CbGpPWpGaD
Carvedilol—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000196	0.000872	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—ankylosing spondylitis	0.000196	0.00087	CcSEcCtD
Carvedilol—GJA1—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000196	0.0153	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000196	0.0153	CbGdCrCtD
Carvedilol—ADRA1D—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000194	0.000927	CbGpPWpGaD
Carvedilol—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000194	0.000863	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000194	0.000861	CcSEcCtD
Carvedilol—Vomiting—Betamethasone—ankylosing spondylitis	0.000192	0.000855	CcSEcCtD
Carvedilol—Vomiting—Dexamethasone—ankylosing spondylitis	0.000192	0.000855	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000191	0.000851	CcSEcCtD
Carvedilol—GJA1—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000191	0.0149	CbGdCrCtD
Carvedilol—GJA1—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000191	0.0149	CbGdCrCtD
Carvedilol—Rash—Dexamethasone—ankylosing spondylitis	0.000191	0.000848	CcSEcCtD
Carvedilol—Rash—Betamethasone—ankylosing spondylitis	0.000191	0.000848	CcSEcCtD
Carvedilol—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000191	0.000847	CcSEcCtD
Carvedilol—Dermatitis—Betamethasone—ankylosing spondylitis	0.000191	0.000847	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00019	0.000845	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—ankylosing spondylitis	0.00019	0.000844	CcSEcCtD
Carvedilol—Headache—Betamethasone—ankylosing spondylitis	0.000189	0.000842	CcSEcCtD
Carvedilol—Headache—Dexamethasone—ankylosing spondylitis	0.000189	0.000842	CcSEcCtD
Carvedilol—VCAM1—tendon—ankylosing spondylitis	0.000189	0.0768	CbGeAlD
Carvedilol—Asthenia—Prednisone—ankylosing spondylitis	0.000189	0.00084	CcSEcCtD
Carvedilol—Pain—Methotrexate—ankylosing spondylitis	0.000188	0.000837	CcSEcCtD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000188	0.000897	CbGpPWpGaD
Carvedilol—Pruritus—Prednisone—ankylosing spondylitis	0.000186	0.000828	CcSEcCtD
Carvedilol—XDH—Metabolism—B3GNT2—ankylosing spondylitis	0.000185	0.000881	CbGpPWpGaD
Carvedilol—HIF1A—tendon—ankylosing spondylitis	0.000182	0.0739	CbGeAlD
Carvedilol—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000181	0.000806	CcSEcCtD
Carvedilol—GJA1—Betamethasone—Prednisone—ankylosing spondylitis	0.000181	0.0142	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Prednisone—ankylosing spondylitis	0.000181	0.0142	CbGdCrCtD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000181	0.000863	CbGpPWpGaD
Carvedilol—Diarrhoea—Prednisone—ankylosing spondylitis	0.00018	0.000801	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.00018	0.0008	CcSEcCtD
Carvedilol—Nausea—Betamethasone—ankylosing spondylitis	0.00018	0.000799	CcSEcCtD
Carvedilol—Nausea—Dexamethasone—ankylosing spondylitis	0.00018	0.000799	CcSEcCtD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000179	0.000853	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000179	0.000853	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000177	0.000844	CbGpPWpGaD
Carvedilol—GJA1—Betamethasone—Prednisolone—ankylosing spondylitis	0.000177	0.0138	CbGdCrCtD
Carvedilol—GJA1—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000177	0.0138	CbGdCrCtD
Carvedilol—GJA1—tendon—ankylosing spondylitis	0.000177	0.0717	CbGeAlD
Carvedilol—HIF1A—Disease—HLA-A—ankylosing spondylitis	0.000176	0.00084	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000176	0.000837	CbGpPWpGaD
Carvedilol—VEGFA—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000175	0.0137	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000175	0.0137	CbGdCrCtD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000175	0.000834	CbGpPWpGaD
Carvedilol—Urticaria—Methotrexate—ankylosing spondylitis	0.000175	0.000777	CcSEcCtD
Carvedilol—Dizziness—Prednisone—ankylosing spondylitis	0.000174	0.000774	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000174	0.000774	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000174	0.000774	CcSEcCtD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000174	0.000829	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000173	0.000826	CbGpPWpGaD
Carvedilol—VEGFA—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000172	0.0135	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000172	0.0135	CbGdCrCtD
Carvedilol—ADRB3—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000169	0.000804	CbGpPWpGaD
Carvedilol—VEGFA—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000168	0.0131	CbGdCrCtD
Carvedilol—VEGFA—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000168	0.0131	CbGdCrCtD
Carvedilol—Vomiting—Prednisone—ankylosing spondylitis	0.000167	0.000745	CcSEcCtD
Carvedilol—Rash—Prednisone—ankylosing spondylitis	0.000166	0.000738	CcSEcCtD
Carvedilol—Dermatitis—Prednisone—ankylosing spondylitis	0.000166	0.000738	CcSEcCtD
Carvedilol—Headache—Prednisone—ankylosing spondylitis	0.000165	0.000734	CcSEcCtD
Carvedilol—ADRA2C—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000164	0.000782	CbGpPWpGaD
Carvedilol—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000162	0.000721	CcSEcCtD
Carvedilol—ADRA1B—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000161	0.000769	CbGpPWpGaD
Carvedilol—VEGFA—Dexamethasone—Prednisone—ankylosing spondylitis	0.00016	0.0125	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Prednisone—ankylosing spondylitis	0.00016	0.0125	CbGdCrCtD
Carvedilol—Asthenia—Methotrexate—ankylosing spondylitis	0.000158	0.000702	CcSEcCtD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000158	0.000752	CbGpPWpGaD
Carvedilol—Nausea—Prednisone—ankylosing spondylitis	0.000156	0.000696	CcSEcCtD
Carvedilol—VEGFA—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000156	0.0122	CbGdCrCtD
Carvedilol—VEGFA—Betamethasone—Prednisolone—ankylosing spondylitis	0.000156	0.0122	CbGdCrCtD
Carvedilol—Pruritus—Methotrexate—ankylosing spondylitis	0.000156	0.000692	CcSEcCtD
Carvedilol—NDUFC2—tendon—ankylosing spondylitis	0.000154	0.0624	CbGeAlD
Carvedilol—ADRB3—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000153	0.00073	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000151	0.00072	CbGpPWpGaD
Carvedilol—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000151	0.00067	CcSEcCtD
Carvedilol—HIF1A—Signaling Pathways—MMP3—ankylosing spondylitis	0.000149	0.00071	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000148	0.000705	CbGpPWpGaD
Carvedilol—Dizziness—Methotrexate—ankylosing spondylitis	0.000146	0.000647	CcSEcCtD
Carvedilol—ADRA1A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000143	0.000683	CbGpPWpGaD
Carvedilol—Vomiting—Methotrexate—ankylosing spondylitis	0.00014	0.000622	CcSEcCtD
Carvedilol—VEGFA—tendon—ankylosing spondylitis	0.00014	0.0566	CbGeAlD
Carvedilol—Rash—Methotrexate—ankylosing spondylitis	0.000139	0.000617	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—ankylosing spondylitis	0.000139	0.000616	CcSEcCtD
Carvedilol—Headache—Methotrexate—ankylosing spondylitis	0.000138	0.000613	CcSEcCtD
Carvedilol—ADRA2A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000133	0.000635	CbGpPWpGaD
Carvedilol—Nausea—Methotrexate—ankylosing spondylitis	0.000131	0.000581	CcSEcCtD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000114	0.000544	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000114	0.000544	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.00011	0.000524	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000109	0.00052	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.0001	0.000477	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—PTGER4—ankylosing spondylitis	9.98e-05	0.000476	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—PTGER4—ankylosing spondylitis	9.92e-05	0.000473	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	9.79e-05	0.000467	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	9.27e-05	0.000442	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—PTGER4—ankylosing spondylitis	9.27e-05	0.000442	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—PTGER4—ankylosing spondylitis	9.12e-05	0.000435	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—PTGER4—ankylosing spondylitis	9.09e-05	0.000433	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PTGER4—ankylosing spondylitis	9.05e-05	0.000431	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PTGER4—ankylosing spondylitis	9.03e-05	0.00043	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—PTGER4—ankylosing spondylitis	9.01e-05	0.000429	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.89e-05	0.000424	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—B3GNT2—ankylosing spondylitis	8.67e-05	0.000413	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	8.65e-05	0.000412	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.41e-05	0.000401	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.28e-05	0.000395	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	8.1e-05	0.000386	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	7.53e-05	0.000359	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PTGER4—ankylosing spondylitis	7.36e-05	0.000351	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—MMP3—ankylosing spondylitis	7.1e-05	0.000339	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—B3GNT2—ankylosing spondylitis	7.04e-05	0.000336	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—TNF—ankylosing spondylitis	6.92e-05	0.00033	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.83e-05	0.000326	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—MMP3—ankylosing spondylitis	6.47e-05	0.000309	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—B3GNT2—ankylosing spondylitis	6.46e-05	0.000308	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MMP3—ankylosing spondylitis	6.44e-05	0.000307	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MMP3—ankylosing spondylitis	6.43e-05	0.000306	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—MMP3—ankylosing spondylitis	6.41e-05	0.000306	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—MMP3—ankylosing spondylitis	6.33e-05	0.000302	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—B3GNT2—ankylosing spondylitis	6.09e-05	0.000291	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—MMP3—ankylosing spondylitis	5.99e-05	0.000286	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—MMP3—ankylosing spondylitis	5.9e-05	0.000281	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTGER4—ankylosing spondylitis	5.89e-05	0.000281	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTGER4—ankylosing spondylitis	5.37e-05	0.000256	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTGER4—ankylosing spondylitis	5.32e-05	0.000254	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTGER4—ankylosing spondylitis	5.25e-05	0.00025	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—MMP3—ankylosing spondylitis	5.24e-05	0.00025	CbGpPWpGaD
Carvedilol—ADRA2C—tendon—ankylosing spondylitis	4.99e-05	0.0202	CbGeAlD
Carvedilol—ADRA2C—Signaling Pathways—PTGER4—ankylosing spondylitis	4.97e-05	0.000237	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTGER4—ankylosing spondylitis	4.89e-05	0.000233	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	4.87e-05	0.000232	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MMP3—ankylosing spondylitis	4.87e-05	0.000232	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	4.59e-05	0.000219	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	4.57e-05	0.000218	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	4.55e-05	0.000217	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTGER4—ankylosing spondylitis	4.35e-05	0.000207	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP3—ankylosing spondylitis	4.2e-05	0.0002	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTGER4—ankylosing spondylitis	4.04e-05	0.000192	CbGpPWpGaD
Carvedilol—ADRA2A—tendon—ankylosing spondylitis	3.98e-05	0.0161	CbGeAlD
Carvedilol—CYP2E1—tendon—ankylosing spondylitis	3.9e-05	0.0158	CbGeAlD
Carvedilol—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	3.89e-05	0.000185	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP3—ankylosing spondylitis	3.82e-05	0.000182	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP3—ankylosing spondylitis	3.79e-05	0.000181	CbGpPWpGaD
Carvedilol—PTGS1—tendon—ankylosing spondylitis	3.75e-05	0.0152	CbGeAlD
Carvedilol—ADRB2—Signaling Pathways—MMP3—ankylosing spondylitis	3.74e-05	0.000178	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP3—ankylosing spondylitis	3.54e-05	0.000169	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP3—ankylosing spondylitis	3.48e-05	0.000166	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP3—ankylosing spondylitis	3.09e-05	0.000147	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	3e-05	0.000143	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP3—ankylosing spondylitis	2.87e-05	0.000137	CbGpPWpGaD
